MedPath

Assessing Changes in Myocardial Tissue and Blood in Patients With Advanced Heart Disease

Recruiting
Conditions
Congestive Heart Failure
Registration Number
NCT01099982
Lead Sponsor
University of Utah
Brief Summary

Hypothesis:

Tissue and serum samples collected from end-stage heart failure patients receiving left ventricular assist device implantation (LVAD) or heart transplantation will provide information regarding the basic science of heart disease. Tissue and serum samples collected from a limited numbers of "healthy controls" (donor grafts that were not utilized for heart transplantation) will serve as a comparator in research database projects.

Design:

This is a registry project; there are no investigational treatments, drug or procedures associated with participation in registry activities. This project is an organized functional data and tissue data gathering and storing (database) endeavor with specific focus on the functional, structural, and molecular aspects of heart failure. Data collection will not immediately influence the course of treatment for any patient.

Detailed Description

Brief description of procedures:

After informed consent is obtained from the patient, the blood samples will be obtained either during a procedure from access lines inserted for the procedure or they will be drawn when other ordered lab work is done at specific time points during the study. Tissue samples will be obtained at the time of LVAD implantation by keeping the part of the left ventricular apex that the surgeon is removing in order to place the inflow cannula of the LVAD. No extra tissue sample, other than the tissue that has to be removed as a part of a standard LVAD, will be collected.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
300
Inclusion Criteria
  • >18 years of age diagnosed with heart failure undergoing either LVAD implantation or heart transplantation
  • 13 to 18 years of age, specifically, older children with heart failure whose body mass index is large enough to accommodate and LVAD
Exclusion Criteria
  • Neither patient nor patient representative understands spoken English
  • Neither patient nor patient's personal representative is willing to give written consent for participation.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Change in myocardial functionbaseline and 3 months

Myocardial function, measured by left ventricular ejection fraction, will be assessed pre-LVAD implant (baseline) and compared with myocardial function assessed at 3 months post-LVAD implant

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (3)

University of Utah Health Sciences Center

🇺🇸

Salt Lake City, Utah, United States

VA Salt Lake City Health Care System

🇺🇸

Salt Lake City, Utah, United States

Intermountain Medical Center

🇺🇸

Murray, Utah, United States

© Copyright 2025. All Rights Reserved by MedPath